Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Endocrinology

Treatment Strategies & Fertility Considerations

At a Glance

For premenopausal osteoporosis, treatment usually starts by correcting the underlying cause and optimizing calcium, vitamin D, safe exercise, smoking, and alcohol habits. Bone medications are reserved for high-risk cases and require careful pregnancy planning.

In premenopausal women, the “gold standard” of treatment is not a pill or an injection—it is identifying and fixing the underlying cause of your bone loss [1][2]. Because your body is still in its peak years for bone maintenance, many women can see their bone density stabilize or even improve naturally once the contributing cause is removed [3][4].

The First Line: Addressing the Root Cause

If your diagnostic workup found a secondary cause, treating that condition is the most effective way to protect your bones [1].

  • Nutritional Issues: For those with a confirmed diagnosis of celiac disease, a strict gluten-free diet allows the gut to heal so it can properly absorb calcium and vitamin D [3][5].
  • Hormonal Balance: If missed periods (amenorrhea) are the cause, treatment should first address the underlying issue, such as low energy availability, excessive exercise, or endocrine disease. Hormone therapy is individualized, and oral contraceptives can mask menstrual recovery [6][1].
  • Medication Adjustment: If you must take bone-damaging drugs like steroids, your doctor may try to find the lowest effective dose. Do not stop or change prescribed medicines without consulting your clinician. [3][7].

Lifestyle Foundations

Before considering specialized medications, every premenopausal woman should optimize these three pillars:

  1. Nutrition: Ensure you meet age- and pregnancy-appropriate calcium requirements, making up any dietary shortfall with supplements rather than automatically taking a high dose [F033]. Vitamin D levels should be checked and supplemented if you are deficient [1][8].
  2. Specific Exercise: Focus on progressive resistance training and weight-bearing activities. However, jogging, impact activity, and resistance training require modification or professional physical therapy guidance in people with active vertebral fractures. Do not exercise through worsening pain [1].
  3. Risk Reduction: Avoiding smoking and limiting alcohol are essential, as both are directly toxic to bone-building cells [1].

When Medications Are Necessary

Bone-specific medications are generally reserved for high-risk situations, such as when a woman has recurrent fractures or a secondary cause (like chemotherapy or high-dose steroids) that cannot be stopped [2][9]. Medication choice depends on renal function, calcium status, fracture severity, and ongoing risk.

Bisphosphonates (e.g., Alendronate, Zoledronic Acid)

These drugs slow down the cells that break down bone.

  • The Fertility Catch: Bisphosphonates stay in your bone tissue for many years [10][11]. While human pregnancy data following bisphosphonate exposure are limited and do not establish a universal “washout” interval, they are used with caution, and strict contraception is often required based on specific prescribing guidance [10].

Teriparatide (Forteo)

This is an “anabolic” or bone-building agent that mimics a natural hormone to stimulate new bone growth.

  • Usage: It is often used “off-label” for severe cases or Pregnancy-Associated Osteoporosis [12][13].
  • Pregnancy: It must not be used during pregnancy [1].

Denosumab (Prolia)

This is a twice-yearly injection that stops bone breakdown.

  • The “Rebound” Warning: Denosumab must never be stopped abruptly, and it should not be used in pregnancy. When you stop this medication, bone breakdown can accelerate rapidly, leading to a “rebound” effect that can cause multiple spinal fractures [14][15]. If you start denosumab, you must have a carefully timed transition plan to switch to another medication (like a bisphosphonate) when you stop [16][17].

Planning for the Future

Treatment for premenopausal osteoporosis is highly individualized. Because these medications can affect your health and future pregnancies for years, they should be managed by a specialist (usually an endocrinologist) who can balance your immediate bone safety with your long-term family goals [2][11]. Always discuss your timeline for future children before starting any bone-specific therapy.

Common questions in this guide

What is usually the first step in treating premenopausal osteoporosis?
The first step is usually to identify and treat the reason bone loss is occurring, such as celiac disease, low energy availability, an endocrine problem, or a bone-affecting medicine. Calcium and vitamin D needs, appropriate exercise, smoking, and alcohol use should also be addressed.
When are bone medicines considered for premenopausal osteoporosis?
Bone-specific medicines are generally reserved for people at high risk, such as those with recurrent fractures or a secondary cause that cannot be removed, including some chemotherapy or high-dose steroid situations. The choice depends on kidney function, calcium status, fracture severity, and ongoing risk.
Can I take bisphosphonates if I may want to become pregnant?
Bisphosphonates can remain in bone for many years, and human pregnancy data after exposure are limited. There is no universal washout period, so your clinician will give individualized advice and may recommend reliable contraception while treatment is being considered or used.
What should I know before starting denosumab?
Denosumab should not be used during pregnancy and should never be stopped abruptly. Stopping can cause rapid rebound bone breakdown and multiple spinal fractures, so a clinician should create a timed transition plan, often involving a bisphosphonate.
Is teriparatide safe during pregnancy?
Teriparatide must not be used during pregnancy. It may be considered off-label for severe premenopausal osteoporosis or pregnancy-associated osteoporosis, but an experienced specialist should weigh the risks and benefits.
Can treating the underlying cause improve bone density?
Bone density may stabilize or improve after the contributing problem is corrected, especially when nutrition, hormone balance, celiac disease, or medication exposure is addressed. Your clinician can decide when to repeat a DXA scan based on the cause, treatment, and fracture risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since I am premenopausal, do I meet the specific criteria for starting medication, or should we focus only on my secondary causes first?
  2. 2.If we decide on a bisphosphonate, how many years does it stay in the bone, and what is the individualized advice before trying to conceive?
  3. 3.What is our specific transition plan for when I eventually stop denosumab to ensure I don't experience rebound bone loss or new fractures?
  4. 4.Are there specific exercises or physical therapists you recommend that focus on safe resistance training without putting my spine at risk?
  5. 5.If we treat my underlying condition (like celiac or thyroid issues), how long should we wait before doing another DXA to see if my bone density improves naturally?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Osteoporosis in premenopausal women.

    Langdahl BL

    Current opinion in rheumatology 2017; (29(4)):410-415 doi:10.1097/BOR.0000000000000400.

    PMID: 28394826
  2. 2

    Premenopausal osteoporosis.

    Conradie M, de Villiers T

    Climacteric : the journal of the International Menopause Society 2022; (25(1)):73-80 doi:10.1080/13697137.2021.1926974.

    PMID: 34036859
  3. 3

    Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF.

    Pepe J, Body JJ, Hadji P, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(8)) doi:10.1210/clinem/dgaa306.

    PMID: 32453819
  4. 4

    High prevalence of laboratory abnormalities indicative of secondary osteoporosis detected by systematic testing.

    Shah N, Galitzer H, Yalamanchi S, Sellmeyer DE

    JBMR plus 2025; (9(7)):ziaf089 doi:10.1093/jbmrpl/ziaf089.

    PMID: 40584155
  5. 5

    Drug-Induced Osteoporosis.

    Gasser RW, Kocijan R, Zendeli A, Resch H

    Journal of clinical medicine 2026; (15(3)) doi:10.3390/jcm15030993.

    PMID: 41682673
  6. 6

    Management of bone health in patients with celiac disease: Practical guide for clinicians.

    Duerksen D, Pinto-Sanchez MI, Anca A, et al.

    Canadian family physician Medecin de famille canadien 2018; (64(6)):433-438.

    PMID: 29898932
  7. 7

    Linking the relationship between drug-induced osteoporosis and the gut microbiota.

    Martiniakova M, Sarocka A, Penzes N, et al.

    Frontiers in endocrinology 2026; (17()):1818207 doi:10.3389/fendo.2026.1818207.

    PMID: 42305264
  8. 8

    Secondary osteoporosis.

    Sheu A, Diamond T

    Australian prescriber 2016; (39(3)):85-7 doi:10.18773/austprescr.2016.038.

    PMID: 27346916
  9. 9

    Premenopausal Osteoporosis.

    Cohen A

    Endocrinology and metabolism clinics of North America 2017; (46(1)):117-133 doi:10.1016/j.ecl.2016.09.007.

    PMID: 28131128
  10. 10

    Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis.

    Stumpf U, Kraus M, Hadji P

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2021; (32(11)):2383-2387 doi:10.1007/s00198-021-06008-z.

    PMID: 34041561
  11. 11

    Comparative Effectiveness of Therapeutic Interventions in Pregnancy and Lactation-Associated Osteoporosis: A Systematic Review and Meta-analysis.

    Anagnostis P, Lampropoulou-Adamidou K, Bosdou JK, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(3)):879-901 doi:10.1210/clinem/dgad548.

    PMID: 37708365
  12. 12

    Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.

    Cohen A, Shiau S, Nair N, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(10)) doi:10.1210/clinem/dgaa489.

    PMID: 32876328
  13. 13

    Pregnancy- and lactation-associated osteoporosis: A position statement of the IAPM, IOF, ECTS, ESCEO, IMS, and EMAS.

    Hadji P, Athanasiadis A, Brandi ML, et al.

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2026; doi:10.1002/ijgo.71203.

    PMID: 42464584
  14. 14

    Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature.

    Tay WL, Tay D

    Endocrinology and metabolism (Seoul, Korea) 2022; (37(2)):183-194 doi:10.3803/EnM.2021.1369.

    PMID: 35417954
  15. 15

    Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.

    Kendler DL, Cosman F, Stad RK, Ferrari S

    Advances in therapy 2022; (39(1)):58-74 doi:10.1007/s12325-021-01936-y.

    PMID: 34762286
  16. 16

    Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries.

    Sendhil SR, Cadarette SM, Aggarwal S, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025; doi:10.1007/s00198-025-07668-x.

    PMID: 41143882
  17. 17

    New and emerging concepts in the use of denosumab for the treatment of osteoporosis.

    Lewiecki EM

    Therapeutic advances in musculoskeletal disease 2018; (10(11)):209-223 doi:10.1177/1759720X18805759.

    PMID: 30386439

This page is for informational purposes only and does not replace medical advice. An endocrinologist and other clinicians should help you weigh medication, fracture, and future pregnancy considerations for your situation.

Get notified when new evidence is published on premenopausal osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.